Antibody

#Antibody #Clinical trials #Gene therapy #MND #Motor neurone disease #Therapeutics

Joint fund to accelerate search for motor neurone disease treatments

Medical research charity LifeArc and the MND Association have established a £1 million joint translational research fund to support researchers developing treatments for Motor Neurone Disease (MND). Despite recent advances, there is still no effective clinical treatment for MND. Each organisation is contributing £500,000 to the fund. Researchers from across… Read More

#News

#Antibody #Cancer #Immuno-oncology #Immunotherapy

Twist Biopharma: antibody candidates against GPCR therapeutic targets

Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market. Twist Biopharma, an arm of Twist Bioscience, was built… Read More

#Exclusive Content #News

#Antibody #Bacteria #Drug development #Drug discovery #Research study

New model can predict how bacteria develop antibiotic resistance

Using theoretical models of bacterial metabolism and reproduction, scientists can predict the type of resistance that bacteria will develop when they are exposed to antibiotics. This has now been shown by an Uppsala University research team, in collaboration with colleagues in Cologne, Germany. The study is published in the journal… Read More

#News

#Antibody #Cancer #Cancer research #Immune cells #Research

Cancer immunotherapy may also treat autoimmune diseases

A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The findings, which include studies in cell lines and animal models, appeared in JCI Insight and focus on a protein called CD6 as… Read More

#Cancer Research #News

#AI #Antibody #Drug discovery

Antiverse raises funds to advance its AI antibody drug discovery platform

Antiverse, a biotechnology company developing a computational antibody drug discovery platform, has raised seed funding totalling £1.4 million ($2 million USD), comprising new investment and match funding from the UKI2S Innovate Accelerator. The funding will be used to further develop Antiverse’s AI antibody drug discovery platform, which rapidly and accurately… Read More

#News

#Antibody #Assay development optimisation & technology

LSBIO acquires Absolute Antibody

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast. LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits,… Read More

#News #Trending News

#Antibody #Covid-19 #Immunology / Virology & Vaccines #T-Cells

Oxford vaccine stimulates broad antibody and T cell functions

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing Phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions. These findings… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibody #Biologics #Drug discovery #High throughput screening

PerkinElmer invests in Carterra, antibody screening and characterisation expert

Carterra, specialist in label-free high throughput antibody screening and characterisation, has closed on a round of equity financing led by PerkinElmer. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round. The Carterra LSA platform for accelerating the discovery of therapeutic antibodies has become… Read More

#Editor's Choice #News